EMA Panel Recommends Approval for X4 Pharmaceuticals' WHIM Syndrome Treatment
Key Facts
- •The EMA's CHMP adopted a positive opinion recommending the marketing authorization of mavorixafor for WHIM syndrome.
- •A final approval decision from the European Commission is anticipated in the second quarter of 2026.
- •The drug could become the first and only therapy in the EU for WHIM syndrome, an ultra-rare immune disorder.
The EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing authorization of mavorixafor. Developed by X4 Pharmaceuticals, the drug is designed to treat WHIM syndrome, an ultra-rare primary immunodeficiency. If approved, mavorixafor would become the first and only therapy available for patients with this condition in the European Union. A final decision from the European Commission regarding the marketing authorization is anticipated in the second quarter of 2026. This regulatory milestone represents a significant growth catalyst for X4 Pharmaceuticals (Nasdaq: XFOR) as it targets the European market. The recommendation underscores the clinical potential of the drug to address a critical unmet medical need in the rare disease space.
freemium.freemium.cta.signup
freemium.freemium.cta.signup_button